Regulations set down or backstopped by the EU and its agencies cover every aspect of life sciences and health care: Brexit has been billed as an opportunity to rip up the rule book and start again. For many NHS managers and commissioners, rules on procurement and competition create a legal sense of doubt over more collaborative models of organising care. The European Working Time Directive is contentious, and for the life sciences industry, the future of the EMA and the MHRA, and of the Clinical Trials Directive present both serious risks and potential opportunities.
In this context, the Nuffield Trust is bringing together around 20 leaders from the health and social care system including commissioners and providers, academia and government to explore the concerns and opportunities related to regulation for health and social care, including:
- How should British and European medicines and science regulation work together after Brexit? Do we align as closely as possible, or carve out some room for our own way?
- Should the UK aim to diverge from the Clinical Trials Directive, and the Working Time Directive?
- Should we look for ways to reshape NHS competition and procurement law after Brexit? If so, how?
This seminar will be held under the Chatham House rule and is being organised, and associated material produced, by the Nuffield Trust in collaboration with MSD. MSD is sponsoring the meeting.
Chair
Partners
